SG11201912103TA - Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases - Google Patents
Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseasesInfo
- Publication number
- SG11201912103TA SG11201912103TA SG11201912103TA SG11201912103TA SG11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- amino acids
- related diseases
- mitochondrial dysfunction
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004065 mitochondrial dysfunction Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102017000087359A IT201700087359A1 (en) | 2017-07-28 | 2017-07-28 | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION |
PCT/IB2018/055425 WO2019021135A1 (en) | 2017-07-28 | 2018-07-20 | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201912103TA true SG11201912103TA (en) | 2020-01-30 |
Family
ID=60628070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201912103TA SG11201912103TA (en) | 2017-07-28 | 2018-07-20 | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases |
Country Status (22)
Country | Link |
---|---|
US (2) | US11337946B2 (en) |
EP (2) | EP3915553A1 (en) |
JP (2) | JP7266767B2 (en) |
KR (3) | KR102566297B1 (en) |
CN (1) | CN110996935A (en) |
AU (2) | AU2018306540B2 (en) |
BR (1) | BR112020001471A2 (en) |
CA (1) | CA3070197A1 (en) |
CL (1) | CL2020000220A1 (en) |
DK (1) | DK3658132T3 (en) |
ES (1) | ES2923126T3 (en) |
HU (1) | HUE059050T2 (en) |
IT (1) | IT201700087359A1 (en) |
LT (1) | LT3658132T (en) |
MX (2) | MX2020001083A (en) |
MY (1) | MY200975A (en) |
PH (1) | PH12020500190A1 (en) |
PL (1) | PL3658132T3 (en) |
PT (1) | PT3658132T (en) |
RS (1) | RS63422B1 (en) |
SG (1) | SG11201912103TA (en) |
WO (1) | WO2019021135A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700087359A1 (en) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION |
IT201700087376A1 (en) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION |
IT201900002109A1 (en) * | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM |
JP2021038147A (en) * | 2019-08-30 | 2021-03-11 | 国立大学法人 鹿児島大学 | Mitochondrial biosynthesis promoter |
IT202000000442A1 (en) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CHEMOTHERAPY |
IT202000000454A1 (en) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR THE PREVENTION AND TREATMENT OF CANCER |
IT202000021664A1 (en) * | 2020-09-14 | 2022-03-14 | Iaf Network S P A | BALANCED AMINO ACID FORMULATION |
TW202308604A (en) * | 2021-05-10 | 2023-03-01 | 國立大學法人東北大學 | Composition for increasing muscle mass |
IT202100029726A1 (en) * | 2021-11-24 | 2023-05-24 | Professional Dietetics Spa | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF CORNEAL LESIONS |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE555780T1 (en) * | 1997-10-24 | 2012-05-15 | John P Blass | DIETARY SUPPLEMENTS FOR METABOLIC BRAIN DISORDERS |
DE10000577A1 (en) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity |
ITTO20010580A1 (en) * | 2001-06-15 | 2002-12-15 | Professional Dietetics Srl | AMINO ACID BASED COMPOSITIONS FOR IMPROVING THE MYOCARDIC VENTRICULAR FUNCTION IN PATIENTS WITH DIABETES. |
ITTO20010804A1 (en) | 2001-08-08 | 2003-02-08 | Professional Dietetics Srl | COMPOSITIONS BASED ON AMINO ACIDS, SUITABLE FOR THERAPY FOR CICATRIZATION AND / OR REPAIR OF INJURIES AND INJURIES, IN PARTICULAR FOR THE APP |
US6620850B2 (en) | 2001-09-19 | 2003-09-16 | University Of Florida | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors |
US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
ITTO20030789A1 (en) | 2003-10-07 | 2005-04-08 | Professional Dietetics Srl | COMPOSITION BASED ON AMINO ACIDS FOR TREATMENT |
WO2007049818A1 (en) | 2005-10-27 | 2007-05-03 | Ajinomoto Co., Inc. | Anti-fatty liver, anti-obesity or hypolipidemic composition |
US7982066B2 (en) * | 2005-12-09 | 2011-07-19 | Novalife, Inc. | High protein supplement |
JP2007161642A (en) | 2005-12-14 | 2007-06-28 | Kyowa Hakko Kogyo Co Ltd | Alcoholic liver injury retarder |
TWI551288B (en) | 2011-02-17 | 2016-10-01 | Ea Pharma Co Ltd | Antimicrobial activity enhancer for chemotherapeutic agents |
WO2012147901A1 (en) | 2011-04-28 | 2012-11-01 | 味の素株式会社 | Composition for mitigating anticancer drug side effects |
US20130084378A1 (en) | 2011-09-30 | 2013-04-04 | Daesang Corporation | Amino acid seasoning compositions comprising l-glutamic acid and l-lysine |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
WO2013188874A1 (en) | 2012-06-15 | 2013-12-19 | Gencia Corporation | Methods of mitigating side effects of radiation exposure and chemotherapy |
CN102772407B (en) | 2012-08-01 | 2014-09-17 | 岳茂兴 | Pharmaceutical composition for promoting nerve damage restoration and application thereof |
US9597367B2 (en) * | 2013-04-19 | 2017-03-21 | Bioventures, Llc | Methods for improving muscle and heart function |
US10226441B2 (en) | 2014-12-09 | 2019-03-12 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
MX357998B (en) * | 2015-03-20 | 2018-07-11 | Antonio Hernandez Miramontes Jorge | A mixture of carboxylic acids, more specifically, citric acid, succinic acid, fumaric acid, malic acid, and their use for the treatment of patients with chronic renal failure, acute renal failure, acute or chronic hepatopathies associated with hyperamonemia, congenital diseases with enzymatic alterations in the urea cycle, as well as clinical conditions associated with a negative nitrogen balance. |
CN107708683A (en) | 2015-05-11 | 2018-02-16 | 纽卡斯尔创新有限公司 | Amino acid supplementation |
MY187022A (en) | 2015-05-14 | 2021-08-26 | Professional Dietetics Spa | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy |
US20180221457A1 (en) | 2015-07-31 | 2018-08-09 | Val-Chum, Limited Partnership | Glycerol-3-phosphate phosphatase activators |
BR112018010200B1 (en) | 2015-11-27 | 2022-05-17 | Doublegood Ab | Dosage of a food supplement, use of food supplement dose, and food composition. |
CN110678172A (en) | 2017-04-28 | 2020-01-10 | 胺细拉健康公司 | Amino acid compositions for treating traumatic brain injury and methods of use thereof |
IT201700087376A1 (en) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION |
IT201700087359A1 (en) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION |
CN118078810A (en) | 2017-10-02 | 2024-05-28 | 佛罗里达大学研究基金会公司 | Materials and methods for inhibiting tumor growth |
WO2019172287A1 (en) * | 2018-03-05 | 2019-09-12 | 味の素株式会社 | Composition for enhancing cognitive function, composition for remedying anxiety symptoms, and composition for suppressing cerebral atrophy |
IT201800006725A1 (en) | 2018-06-27 | 2019-12-27 | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF LIVER DISEASES | |
IT201900002109A1 (en) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM |
US20220394508A1 (en) | 2019-11-11 | 2022-12-08 | Lg Electronics Inc. | Vehicular distributed antenna system operating in wireless communication system and method for operating same |
IT202000000454A1 (en) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR THE PREVENTION AND TREATMENT OF CANCER |
IT202000000442A1 (en) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CHEMOTHERAPY |
WO2022266480A1 (en) | 2021-06-17 | 2022-12-22 | Axcella Health Inc. | Methods of predicting liver fat content and uses thereof |
-
2017
- 2017-07-28 IT IT102017000087359A patent/IT201700087359A1/en unknown
-
2018
- 2018-07-20 PL PL18753465.6T patent/PL3658132T3/en unknown
- 2018-07-20 PT PT187534656T patent/PT3658132T/en unknown
- 2018-07-20 KR KR1020207003492A patent/KR102566297B1/en active IP Right Grant
- 2018-07-20 KR KR1020247014645A patent/KR20240063205A/en active Application Filing
- 2018-07-20 MY MYPI2020000106A patent/MY200975A/en unknown
- 2018-07-20 CA CA3070197A patent/CA3070197A1/en active Pending
- 2018-07-20 LT LTEPPCT/IB2018/055425T patent/LT3658132T/en unknown
- 2018-07-20 MX MX2020001083A patent/MX2020001083A/en unknown
- 2018-07-20 EP EP21174744.9A patent/EP3915553A1/en active Pending
- 2018-07-20 KR KR1020237026054A patent/KR20230117642A/en active Application Filing
- 2018-07-20 US US16/634,330 patent/US11337946B2/en active Active
- 2018-07-20 SG SG11201912103TA patent/SG11201912103TA/en unknown
- 2018-07-20 EP EP18753465.6A patent/EP3658132B1/en active Active
- 2018-07-20 ES ES18753465T patent/ES2923126T3/en active Active
- 2018-07-20 BR BR112020001471-0A patent/BR112020001471A2/en unknown
- 2018-07-20 WO PCT/IB2018/055425 patent/WO2019021135A1/en active Application Filing
- 2018-07-20 DK DK18753465.6T patent/DK3658132T3/en active
- 2018-07-20 JP JP2019566579A patent/JP7266767B2/en active Active
- 2018-07-20 HU HUE18753465A patent/HUE059050T2/en unknown
- 2018-07-20 CN CN201880047542.0A patent/CN110996935A/en active Pending
- 2018-07-20 RS RS20220627A patent/RS63422B1/en unknown
- 2018-07-20 AU AU2018306540A patent/AU2018306540B2/en active Active
-
2020
- 2020-01-27 MX MX2022010774A patent/MX2022010774A/en unknown
- 2020-01-27 CL CL2020000220A patent/CL2020000220A1/en unknown
- 2020-01-27 PH PH12020500190A patent/PH12020500190A1/en unknown
-
2022
- 2022-04-20 US US17/724,537 patent/US11957651B2/en active Active
-
2023
- 2023-03-08 JP JP2023035509A patent/JP2023071939A/en active Pending
- 2023-11-14 AU AU2023266256A patent/AU2023266256A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201912103TA (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
IL284371B (en) | Amino acid compositions and methods for the treatment of liver diseases | |
IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
IL253195B (en) | Pharmaceutical compositions comprising synthetic glycans for use in treatment of gastrointestinal diseases and methods of preparing them" | |
IL273959A (en) | Methods and compositions for the treatment of rare diseases | |
EP3337465A4 (en) | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases | |
PL3577135T3 (en) | A pharmaceutical composition for use in the treatment or prevention of c5-related diseases | |
IL272336A (en) | Amino acid compositions for the treatment of neuronal injury | |
IL274578A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
ZA202007834B (en) | Compositions comprising amino acids for use in the prevention and treatment of liver diseases | |
EP3185862A4 (en) | Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases | |
PL3294279T3 (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
IL280389A (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
IL272495A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
SG11201912098SA (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
PL3515409T3 (en) | Complex and compositions for the treatment of ophthalmic and dermatological diseases | |
EP3265108A4 (en) | Peptides and compositions comprising same and uses thereof in the treatment of diseases | |
PL3006027T3 (en) | Compositions comprising amino acids for use in the treatment of systemic inflammation state associated to stroke in patients with dysphagia | |
IL265911A (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
IL243402A0 (en) | Methods of identifying compositions which can be used in the treatment of heart diseases and uses of such compounds in the treatment of same |